Jones Daniel A, Choudry Fizzah, Mathur Anthony
Department of Cardiology, London Chest Hospital, London-UK.
Anadolu Kardiyol Derg. 2013 May 29. doi: 10.5152/akd.2013.167.
The rapid translation from bench to bedside that has been seen in the application of regenerative medicine to cardiology has led to exciting new advances in our understanding of some of the fundamental mechanisms related to human biology. The first generation of cells used in phase I-II trials (mainly bone marrow mononuclear cells) are now entering phase III clinical trials with the goal of producing a cell based therapeutic that can change the outcome of cardiac disease. First generation cell therapy appears to have addressed safety concerns as well as showing 'activity' in numerous published meta- analyses. With the knowledge gained to date, the field is moving towards the next generation of cells-the 'engineered' cell-that have been developed to display a phenotype that will further enhance the myocardial repair/salvage process. This almanac review covers the latest basic research that may soon have application to humans as well as the results of the latest clinical trials.
再生医学在心脏病学中的应用实现了从实验室到临床的快速转化，这使我们对一些与人类生物学相关的基本机制有了令人兴奋的新认识。第一代用于I-II期试验的细胞（主要是骨髓单个核细胞）目前正进入III期临床试验，目标是开发出一种基于细胞的疗法，以改变心脏病的治疗结果。第一代细胞疗法似乎已解决了安全性问题，并且在众多已发表的荟萃分析中显示出“活性”。基于目前所获得的知识，该领域正朝着新一代细胞——“工程化”细胞——迈进，这种细胞经过开发，具有能进一步增强心肌修复/挽救过程的表型。本综述涵盖了可能很快应用于人类的最新基础研究以及最新临床试验的结果。
